- Home
- /
- High Courts
- /
- Delhi High Court
- /
- Delhi High Court Restrains...
Delhi High Court Restrains Manufacture, Sale of Glucose Test Strips Copying Chinese Company Sinocare
Ayushi Shukla
13 Nov 2025 6:48 PM IST
The Delhi High Court has temporarily restrained several Indian firms from manufacturing, marketing, or selling blood glucose test strips or any other medical devices under the brand names “Safe AQ” and “Safe Accu”, after Chinese medical device maker Changsha Sinocare Inc. raised objection. The injunction will remain in place until March 3, 2026.A single bench of Justice Tejas...
The Delhi High Court has temporarily restrained several Indian firms from manufacturing, marketing, or selling blood glucose test strips or any other medical devices under the brand names “Safe AQ” and “Safe Accu”, after Chinese medical device maker Changsha Sinocare Inc. raised objection.
The injunction will remain in place until March 3, 2026.
A single bench of Justice Tejas Karia passed the order on November 7, 2025, while hearing Sinocare's interim plea in a suit seeking permanent injunctions, damages, and other relief. The Indian firms had previously acted as Sinocare's distributors in India.
Sinocare, which specializes in biosensing technology and glucose monitoring systems, said its Indian subsidiary markets and sells products under the marks “Safe AQ” and “Safe Accu”, which are registered and used globally. The company claimed the firms deliberately copied its distinctive trade dress, including red-and-white or blue-and-white color schemes with a wave design for its packaging. It also claimed that these firms were also manufacturing and selling counterfeit products using identical trade dress and branding.
The court noted that Sinocare had prior and continuous use of the marks, earning considerable goodwill, and that the rival products were deceptively similar in layout, color, wave design, and overall packaging. It observed that the likelihood of consumer confusion was “real and substantial."
Since the companies had previously been distributors, the court said their use of the marks appeared “devoid of bona fide”. It concluded that a prima facie case existed in Sinocare's favor and that continued use of the infringing marks could result in loss of distinctiveness and consumer trust.
The court noted that the material on record demonstrated Sinocare's prior and continuous use of the “Safe AQ” and “Safe Accu” marks and associated trade dress over a substantial period. It observed that the company's promotional efforts had earned considerable goodwill and the marks had come to be exclusively associated with Sinocare.
It therefore granted an ad-interim injunction preventing the Indian firms from using “Safe AQ”, “Safe Accu”, or any deceptively similar branding on glucose test strips or other medical devices.
The matter will next be listed on March 03, 2026.
Case Title: Changsha Sinocare Inc & Anr v. Mr. Rajesh Kumar & Ors
Citation: 2025 LiveLaw (Del) 1494
Case Number: CS (COMM) 1188/2025
For the Plaintiffs: Advocates Pramod Kumar Singh, Aastha Sharma and Jahanvi Sharma